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ABSTRACT
Background: In Finland, selective internal radiation therapy (SIRT) is at present the preferred first-line
loco-regional therapy for uveal melanoma patients with hepatic metastases not suitable for surgery.
We retrospectively evaluate the outcome and safety of SIRT in this group of patients.
Material and methods: Yttrium-90 microspheres were delivered via the hepatic artery into the circula-
tion of metastases from uveal melanoma in 18 patients with a predicted life expectancy of more than
three months in three Finnish tertiary referral centers between November 2010 and December 2015.
Progression-free survival (PFS), toxicity and overall survival (OS) were evaluated. Patients with historical
uveal melanoma without extrahepatic metastases, who had received systemic chemotherapy as first-
line treatment for their hepatic metastases at the Helsinki University Hospital between January 2006
and May 2010, were used as a historical control group.
Results: Partial response and stable disease were observed in three (17%) and eight (44%) patients,
respectively; one patient was not evaluable for response. Median PFS after SIRT was 5.6 (range,
1.3–40.8) months. Median OS after SIRT was 13.5 (range, 3.6–44.8) months compared with 10.5 (range,
3.0–16.5; p¼ .047) months for the historical chemotherapy group. Among patients who received SIRT
as first-line treatment, the median OS was 18.7 (range, 8.2–44.8) months, significantly longer than that
of the chemotherapy group (10.5 months, p¼ .017). There were no treatment-related deaths. Toxicity
was mainly WHO grade 1–2 and self-limited.
Conclusion: SIRT is a feasible and safe treatment for liver metastases in patients with uveal melanoma.
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Background
Uveal melanoma is the most common primary intraocular
malignancy in adults. The mean age-adjusted incidence is 5.1
per million [1]; but it increases from Southern to Northern
latitudes from two to over eight per million [2].
Consequently, Finland is among countries with the highest
incidence in the world. Unlike skin melanoma, the age-
adjusted incidence of uveal melanoma has remained stable
[1,3]. However, because of the aging population structure in
Europe, the crude incidence of uveal melanomas is increasing
[4]. At the time of diagnosis, the disease is limited to the eye
in 98% of the patients even when the intraocular tumor is
large [5]. The most common conservative treatment is plaque
brachytherapy with ruthenium or iodine isotopes.
Enucleation is preferred for patients with large advanced
tumors when there is only a minor possibility to save useful
vision [6]. Despite successful treatment of the primary tumor,
over 50% of the patients develop clinical metastases over the
next 30 years [7]. According to the Collaborative Ocular
Melanoma Study (COMS), 25% of the patients with medium
size to large choroidal melanoma had developed metastases
at five years, and 34% of the patients had metastatic disease
at 10 years [8].
Uveal melanoma spreads hematogenously. The most com-
mon site for metastases is the liver (>90%) followed by the
lungs [8,9]. Clinical risk factors for metastatic disease are large
tumor size, ciliary body extension and extraocular growth of
the primary tumor [10]. Chromosomal abnormalities such as
monosomy 3 and amplification of 8q chromosome, mutation
in BAP1 and gene expression profile class 2 identify those at
highest risk of metastasis [11], especially when combined
with clinical predictors [12,13].
Prognostic models for risk factors associated with survival
have been developed [14,15]. Similarly, staging for patients
with newly identified metastases have been proposed and
validated [16–18]. These models share performance index, a
measure of metastatic extent such as the largest dimension
of the largest metastasis, and serum levels of transaminases,
lactate dehydrogenase (LDH) and alkaline phosphatase (ALP).
Prognosis in metastatic uveal melanoma is poor. The
median overall survival (OS) of 249 patients from seven
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European ocular oncology centers was 13.5 months, and 53%
of the patients survived >1 year, 22% survived >2 years and
10% survived >3 years [17]. In this multicenter study, the
patient population was heterogenous and were treated with
a wide spectrum of different treatment modalities beginning
from best supportive care to liver resection.
So far none of the new, effective systemic treatments for
cutaneous melanoma has shown substantial efficacy as a
treatment for metastatic uveal melanoma. Therefore, several
locoregional treatments are in use for metastatic uveal mel-
anoma limited to the liver, such as liver resection, transarte-
rial chemoembolization (TACE), hepatic intra-arterial
chemotherapy (HIA), percutaneous hepatic perfusion using
melphalan, isolated hepatic perfusion (IHP), immunoemboli-
zation, drug-eluting beads and, more recently, selective
internal radiation therapy (SIRT) also known as radioemboli-
zation [19,20].
Liver metastases receive approximately 80–100% of the
blood flow from the hepatic artery, whereas normal liver par-
enchyma is supplied by the portal vein. The basis of SIRT is
to implant into the hepatic arterial circulation microspheres
composed of resin or glass particles bound to yttrium-90, a
high-energy beta-emitting isotope with a half-life of 64.2 h
and an average tissue penetration of 2.5mm. The resin bead
microspheres have a median diameter of 35 mm, which makes
them small enough to penetrate into the tumor circulation
but too large to enter capillaries and to spread to the
lungs [21,22].
Before SIRT became available for liver resection, and to a
much lesser extent TACE, were the only locoregional treat-
ments available in Finland. If patients were not suitable for
resection or TACE, chemotherapy was the remaining treat-
ment option for these patients. The introduction of SIRT was
therefore a welcomed new treatment modality for this group
of patients with limited treatment options. In this retrospect-
ive study, we reviewed consecutive patients with hepatic
metastases from uveal melanoma treated with SIRT in
Finland between 2010, when this treatment was introduced
in Finland, and 2015. We compared the outcome with a his-
toric cohort of patients fulfilling the inclusion criteria we
used for SIRT, treated with systemic chemotherapy for meta-
static uveal melanoma between 2006 and 2010 at the
Helsinki University Hospital.
Material and methods
Patients
Patients who had undergone SIRT treatment for metastatic
uveal melanoma and who had a predicted life expectancy of
more than three months were eligible to this study. Life
expectancy was clinically estimated based on the perform-
ance status, organ functions, progression rate based on con-
secutive radiological imaging and tumor burden. Inclusion
and exclusion criteria for SIRT treatment are listed in Table 1.
In Finland, the diagnosis and treatment of primary uveal
melanoma is centralised to the Department of
Ophthalmology at the Helsinki University Hospital. Treatment
of metastatic uveal melanoma is carried out in regional
oncology units. SIRT is available in the Helsinki, Turku and
Oulu University Hospitals. Data were collected from these
three institutions. Approval from the independent
Institutional Review Board for data collection was applied
separately from each university hospital.
A total of 19 uveal melanoma patients with liver metasta-
ses were treated with SIRT between November 2010 and
December 2015. One patient was excluded because of a pre-
dicted life expectancy less than three months. Eleven of the
remaining 18 patients were treated in Helsinki, 4 in Turku,
and 3 in Oulu. Characteristics of patients receiving SIRT are
listed in Table 2.
In order to compare outcome of treatment modalities,
data were collected from consecutive patients with meta-
static uveal melanoma limited to the liver receiving chemo-
therapy at Helsinki University Hospital between January 2006
and May 2010. A total of 14 patients with metastatic uveal
melanoma were identified during this time. The remaining
eight patients fulfilled the SIRT inclusion criteria and were
thus eligible as controls.
Methods
Extrahepatic metastases were excluded using positron-emis-
sion tomography/computed tomography (PET/CT), contrast-
enhanced computed tomography (CT) or magnetic resonance
imaging (MRI).
Liver angiography was performed approximately two weeks
before the treatment to analyse individual vascular structures.
Table 1. Inclusion and exclusion criteria for SIRT.
Inclusion Exclusion
Metastases limited to liver Extrahepatic metastases
WHO 2 Ascites
If both liver lobes involved, portal vein free from tumor Previous hepatic radiation
Adequate coagulation parameters
INR <1.5 or TT >25%, APTT normal, Tromb >100 E9/l), Hcr >30%
Pregnancy
Adequate liver function
S-Bil <34 mmol/l, S-Alb >30 g/l, AST <175/225 U/l (female/male), ALT <225 U/l
–
Adequate kidney function –
Adequate bone marrow function
B-leuk >2.5, B-neut >1.5, B-tromb >100, Hcr >30%
–
Life expectancy >3 months –
WHO: performance status; INR: international normalized ratio (reference value: 0.7–1.2); TT: thrombin time (70–130%);
APTT: activated partial thromboplastin time (28–37 s); Tromb: thrombocytes (150–360 E9/l); Hcr: hematocrit (female/male
35–46/39–50%); S-Bil: serum bilirubin (<20 mmol/l); S-Alb: serum albumin (36–45 g/l); AST: aspartate aminotransferase
(female/male 15–35/15–45 U/l); ALT: alanine aminotransferase (female/male<35/50 U/l); B-leuk: leucocytes (3.4–8.2 E9/l);
B-neut: neutrophils (1.5–6.7 E9/l).
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At the same time, non-target extrahepatic vessels were
embolised. Technetium (99mTc)-macroaggregated albumin was
injected into the hepatic arteries, followed by whole body scan-
ning and single-photon emission computed tomography
(SPECT) to detect unintentional delivery of the microspheres
into extrahepatic organs and to estimate the degree of shunting
to the lungs.
To calculate the activity delivered to each liver lobe,
three-phase liver CT was used to measure the volumes of the
tumors in relationship to that of the liver. In order to proceed
to SIRT, less than 50% of the liver was allowed to be infil-
trated by metastases. The activity of yttrium-90 in the micro-
spheres was calculated by using the body surface area (BSA)
method, which assumes that BSA is correlated with the size
of the liver [21]. The right and the left lobe were treated in
one or two sessions at 2–4 weeks intervals. The median total
dose administered was 1.9 GBq per patient (range, 0.7–2.54).
Bremsstrahlung scanning was done the day after the treat-
ment to evaluate the distribution of microspheres. After
treatment, the patients were clinically assessed and labora-
tory tests were taken every two weeks for two months, to
monitor acute toxicity. Dexamethasone (4.5mg b.i.d.) com-
bined with a proton-pump inhibitor was offered for three to
four weeks after SIRT to alleviate possible side effects
of radiation.
Data of side effects were collected retrospectively from
the patient charts. Hepatic toxicity was evaluated by using
the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0.
Response was evaluated according to the Response
Evaluation Criteria in Solid Tumours (RECIST) version 1.1 [23].
The first CT scan to evaluate response after the treatment
were made in Oulu at six weeks, in Helsinki at two months,
and in Turku at three months after SIRT, and thereafter at
three-month intervals until progression. The same
radiological examinations used at baseline were also used for
monitoring response. In Helsinki, CT was used, in Oulu MRI,
and in Turku PET-CT or MRI. CT scans were performed for 12
patients, MRI for 3, MRIþCT for 2 and PET-CT for 1 patient.
The response evaluation was performed by the interventional
radiologist for all patients but due to the retrospective nature
of this study six patients did not have a response evaluation
CT scan available after the baseline imaging.
Statistical methods
Distant metastasis-free survival (DMFS) was measured from
the day of diagnosis of primary uveal melanoma to radio-
logical confirmation of liver metastases. Progression-free sur-
vival (PFS) was measured from the day of SIRT to radiological
confirmation of progression. OS was calculated from the day
of SIRT or the first day of chemotherapy to death or last fol-
low-up of the patient. The last follow-up date was 28
December 2017. OS for both groups was estimated by using
the Kaplan–Meier analysis. Survival curves were compared
using the log-rank test. A p value <.05 was considered
significant.
Results
Four of the 18 patients had received systemic chemotherapy
prior to SIRT as first-line therapy, and one of these patients
had been treated with two lines of chemotherapy before
SIRT. The median age at the time of the primary tumor was
58 years (range, 26–68 years). Median age at the diagnosis of
metastatic disease was 63 years (range, 32–76 years). Median
time to SIRT after verified hepatic metastases was 3.6 months
(range, 1.2–10.8 months). Seventeen patients underwent SIRT
Table 2. Patient characteristics, response and survival of SIRT group.
Patient Age
DMFS
(months)
WHO
before SIRT
Hepatic tumor
load (%)a Response
PFS
(months)
Extrahepatic
metastasis
after SIRT
Liver
progression
after SIRT
OS
(months)
Elevated
LDH
1 64 52 2 27 NE 3.5 – NE 3.6b Yes
2 68 77 0 16 PD 3.7 – Yes 5.4b Yes
3 76 120 1 11 PD 4.1 – Yes 6.7 No
4 70 25 1 24 SD 5.8 LN, lung Yes 8.2 No
5 55 8 0 20 PD 1.5 Bone Yes 8.9 Yes
6 68 72 0 NA PD 1.3 – Yes 9 No
7 60 25 1 28 PD 5.9 Bone, spleen Yes 9.9 No
8 55 30 0 3 SD 4.4 Brain Yes 10.3b No
9 57 15 1 5 SD 3.6 Lung Yes 12.7 No
10 68 97 0 27 PR 12 Yes 14.3 No
11 63 38 0 0.54 SD 5.6 Lung Yes 20.7b No
12 59 30 0 0.03 NED – – No þ23 No
13 59 16 0 0.66 SD 9 LN, bone, lung,
soft tissue
Yes 23.7 No
14 72 113 0 29 PR 4.3 Lung, bone,
soft tissue
Yes 24.8 Yes
15 50 0 0 6 SD 24.9 Bone Yes 25.2 No
16 65 99 0 10 SD 17.4 Bone Yes 30 No
17 69 49 0 21 PR 18.2 Lung Yes þ40.6 No
18 32 68 0 24 SD 40.8 – Yes þ44.7 No
Age: age at diagnosis of metastatic disease; DMFS: distant metastasis-free survival; WHO: performance status; OS: overall survival; LN: lymph node;
NE: not evaluable; NED: no evidence of disease; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease; þ:
patient alive.
aTumor load cm3/liver volume cm3; bSIRT 2nd/salvage.
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once and one patient four times. Further, patient characteris-
tics are listed in Table 2.
In the chemotherapy group, median age at the diagnosis
of primary disease was 55 years (range, 27–72 years). Median
age at the diagnosis of metastatic disease was 64 years
(range, 38–72years). Single-agent dacarbazine was most com-
monly used as first-line chemotherapy. More detailed
patients’ characteristics are presented in Table 3.
Response to SIRT
The best radiologic response was partial response (PR) for
three patients (17%), eight patients (44%) had stable disease
(SD) and five (28%) had progressive disease (PD). One patient
(6%) was not evaluable for response because the hepatic
metastases could not be reliably measured on CT or MRI.
Prior to the treatment, the metastatic lesions had been found
by laparoscopy. One patient (6%) died before diagnostic
response examination.
Survival
The median follow-up time was 13.5 months (range, 3.6–40.8
months). The median PFS was 5.6 months (range, 1.3–40.8
months). One patient has no evidence of hepatic progression
or extrahepatic metastases. Two other surviving patients pro-
gressed, and one of them also developed extrahe-
patic metastases.
The median OS after verification of hepatic metastases
was 19.6 months (range, 8.8–48 months) for the SIRT group
and 15.5 months for the chemotherapy group
(range, 5.9–19months).
Fifteen patients died during follow-up, including four
patients who received SIRT as second-line salvage therapy
after chemotherapy. Eleven patients (61%) developed extra-
hepatic metastases after SIRT, including pulmonary, subcuta-
neous, bone, lymph node, spleen and cerebral metastases
(Table 2). Sixteen patients (89%) showed progression of hep-
atic metastases and 14 of them received chemotherapy, sur-
gical treatment, immunological treatment, radiation therapy
or a combination of these treatments after progression. The
median OS was 13.5 months (range, 3.6–44.7 months) from
the day of SIRT to death.
In the control group one patient received a combination
of docetaxel and cisplatin, and the remaining seven patients
received dacarbazine as the first-line treatment. Five of the
eight patients received second-line treatment after PD. One
of these five patients received TACE and the remaining four
received chemotherapy as the second-line treatment. Two of
the patients received third-line treatment after progression.
Median OS was 10.5 months (range, 3–16.5 months).
The difference in median OS between the 14 patients
who received SIRT as the first-line treatment (18.7 months;
range, 6.7–44.7) and chemotherapy (10.5 months; range,
3–16.5) was statistically significant (p= .017) (Figure 1). The
median OS (13.5 months; range, 3.6–44.7) of the whole SIRT
group (n¼ 18) was also statistically significant compared with
the chemotherapy group OS (p¼ .047).
The median OS among the four patients who received
SIRT as salvage therapy was significantly lower than that of
those who were treated first-line (7.8 vs. 18.7 months;
p¼ .045) (Figure 2).
To evaluate possible selection bias regarding centers, we
compared the outcome between the two treatment groups
treated in Helsinki University Hospital. Median OS for the 11
SIRT-treated patients was 20.7 months (range, 8.2–44.7
months) compared to 10.5 months for the chemotherapy
group (range, 3–16.5 months; p¼ .01).
Prognostic factors known to influence OS were analyzed
by comparing pretreatment values of serum LDH. Four
patients had elevated LDH. Median OS for patients with ele-
vated LDH (n¼ 4) prior to SIRT appeared to be lower than it
was for patients with normal LDH levels (7.2 vs. 17.5 months;
p = .066). Elevated ALP (n¼ 4) had no statistically significant
influence to OS (p= .83).
We also tested variables suggested to be prognostic fac-
tors for survival in previous studies: gender, hepatic tumor
load, age (younger than vs. older than 60 years) and DMFS
(more vs. less than 24 months). These factors were not statis-
tically significant in our small series.
Toxicity
No SIRT-related deaths were observed. One procedure-related
complication occurred during preparatory arteriography
when a hepatic artery was dissected. SIRT was postponed
and successfully performed four months later.
Eleven patients developed grade 1–2 increase of transami-
nases. One patient had grade 3 and one had grade 4 eleva-
tion of transaminases. Other mild, self-limited toxicity (grade
1–2) was reported for 15 patients, including nausea, abdom-
inal discomfort/pain, tiredness and subfebrility. One patient
was hospitalized due to fever (38.7˚C, grade 1) in relation to
liver toxicity; this patient had received DTIC chemotherapy
five months before SIRT.
The chemotherapy group had more pronounced treat-
ment-related side effects such as nausea, infections, declining
performance status, liver and hematological toxicity.
Discussion
In this nationwide study, we analyzed the outcome of 18
consecutive patients with metastatic uveal melanoma
Table 3. Patient characteristics, treatment and survival in the chemother-
apy group.
Patient Age DMFS
Number of
treatment lines OS (months)
1 72 47 1 3.0
2 69 37 1 6.0
3 67 0 2 6.8
4 66 134 3 8.1
5 38 202 1 12.8
6 48 12 2 13.0
7 42 11 3 14.1
8 63 16 2 16.5
Age: age at metastatic disease; DMFS: distant metastasis-free survival;
OS: overall survival.
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without extrahepatic metastases ineligible for surgery receiv-
ing SIRT as first-line or salvage therapy. The patients had bet-
ter outcome if they received SIRT as a first-line therapy
instead of chemotherapy. As other locoregional treatment
modalities are only rarely used for treating hepatic metasta-
ses of uveal melanoma in Finland, we have limited the
discussion to compare results between studies where SIRT
has been used as treatment for hepatic metastases of
uveal melanoma.
Metastatic uveal melanoma is a rare malignancy. To our
best knowledge, no prospective studies analyzing the efficacy
of SIRT have been reported so far. Only a few retrospective
studies are available with a limited number of patients for
comparison. Differences in the patient characteristics in these
studies complicate a direct comparison. The retrospective
nature of the present study naturally sets limitations when
interpreting results and comparison between the two treat-
ment modalities should be interpreted with caution.
Treatment-related toxicity was observed in both cohorts. In
total, SIRT seemed to be better tolerated than chemotherapy.
Toxicity related to SIRT was mainly self-limited, whereas
chemotherapy was related to more long-lasting side effects.
These findings seem to be in line with what has been
reported elsewhere [24–27].
Our study included 14 patients who received SIRT as the
first-line therapy. The median OS among these patients was
significantly longer compared with the historical control
group treated with the first-line chemotherapy (p= .017). The
median OS of 18.7 months is also the best outcome reported
for patients treated with SIRT in first line. Apparently, only
three earlier studies have reported results on SIRT as first-line
treatment. In the largest of these studies comprising 71
patients (including 13 patients treated with SIRT in first line)
the median OS was 12.3 months for all patients and the
median OS was not reached in the first-line group (Table
4) [28].
Various chemotherapeutic and immunomodulatory agents
and combinations have been investigated showing poor out-
come with median OS from 6 to 14 months [29]. Over 20
years, TACE has been used for the treatment of hepatic
metastases and several chemotherapeutic agents have been
tested [19]. In a review by Agarwala et al. [29], median OS
ranged from 5.0 to 8.9 months for patients receiving TACE
for hepatic metastases from either uveal or cutaneous melan-
oma. More promising survival rates were reported in a retro-
spective analysis of 141 patients, where TACE in combination
with CPT-11 charged microbeads (n¼ 58) was compared with
historical treatments (n¼ 83) (median OS, 16.5 vs. 12.2
months) [30].
Predictive factors for hepatic PFS and OS for 71 patients
were analyzed in the largest reported study so far. In the uni-
variate analysis, female gender, pretreatment metabolic
tumor volume and total glycolic uptake on PET-CT correlated
with hepatic PFS and OS [28]. In another study with 32
Figure 1. Overall survival for patients treated with SIRT in first line (n¼ 14) versus chemotherapy (n¼ 8; p¼ .017).
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patients treated with SIRT as the second-line therapy, the
effect of tumor burden on treatment outcome was evaluated.
Patients with a pretreatment tumor burden of <25% of the
total liver volume had significantly longer PFS than patients
with burden >25% (6.4 vs. 3.0 months) [26]. In our study, the
median liver involvement was only 16% (range, 0.03–29) and
only four patients had a tumor burden >25%, which is low
compared with other studies [26,27]. The smaller tumor vol-
ume could be one explanation why the outcome of our
patients was slightly better compared to that of patients in
other studies. Similar to skin melanoma, larger tumor volume
also correlates with elevated LDH level, which seems to be
related to shorter OS as compared to patients with normal
LDH levels [31]. In our series, only 22% of the patients had
elevated LDH, which supports this observation.
The reported efficacy of SIRT as the second-line treatment
is somewhat more modest (Table 4). The risk of extrahepatic
metastases increases with progression of disease, and prior
Figure 2. Overall survival for patients treated with SIRT in first line (n¼ 14) versus SIRT as second-line treatment (n¼ 4; p¼ .045).
Table 4. Published data on SIRT as treatment for metastatic melanoma limited to the liver.
Study Patients (n)
SIRT 1st and
2nd/salvage
Response (RECIST)
CRþ PR (%)
Response (RECIST)
SD (%) PFS (months) Median OS (months)
Kennedy [24] 11 At least some 2nd/salvage 77 11 NR Not reached; 1-year OS 80%
Klingenstein [25] 13 1st: 2
2nd/salvage: 11
62 15 NR 7.0
Gonsalves [26]a 32 1st: 0
2nd/salvage:
6 56 4.7 10.0
Eldredge-Hindy [28] 71 1st: 13
2nd/salvage: 58
8 52 5.9 1st: not reached
1st:þ salvage: 12.3
Schelhorn [27] 8 1st: 0
2nd/salvage: 8
0 50 1.0 3.0
Xing [32] SIRT: 15 1st: 0
2nd/salvage: 15
– – – 10.9
Present study SIRT: 18
Ctx: 8
1st: 14
2nd/salvage: 4
1st: 8
17 44 5.6 SIRT: 13.5
1st: 18.7
Ctx: 10.5
CR: complete response; Ctx: chemotherapy; OS: overall survival; NR: not reported; PFS: progression-free survival; PR: partial response; SD: stable disease; 1st: first-
line treatment; 2nd/salvage: second-line treatment; þ: patient alive.
aMost patients included also in the study by Eldredge-Hindy [28].
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chemotherapy may expose patients to increased liver toxicity
favoring a strategy to use SIRT as early as possible. In our
study, only four patients received SIRT as the second-line
treatment after chemotherapy. The median OS of these
patients was only 7.8 months. Others have reported similar
or even more modest efficacy for SIRT as a salvage therapy.
The number of patients reported to have received salvage
treatment are small, and the patient populations are heter-
ogenous. There may also be a selection bias, as these
patients have maintained a good performance status, may
have a smaller tumor burden and less aggressive progression
of disease.
In Finland, SIRT is at present the preferred first-line locore-
gional therapy for patients not suitable for surgery, and
chemotherapy is now rarely used as a first-line treatment for
this group of patients. Our present results seem to support
this approach.
Based on the previously reported studies [24–26,28,32] as
well as the results of our study, one can conclude that SIRT
is generally well tolerated and more effective as the first-line
treatment for metastatic uveal melanoma limited to the liver.
Based on the results from this study and another study, it
seems that patients with moderate tumor burden may bene-
fit more from SIRT [26]. The small number of patients limits
the analysis of prognostic factors in our and most of the
other studies [24,25,27,32].
Response evaluation after SIRT is challenging due to
changes in the liver caused by the SIRT treatment itself.
Thus, this also influences reliability of evaluating PFS. As long
as there is no efficient systemic therapy for these patients,
median OS is the most reliable factor to evaluate treat-
ment efficacy.
In the future, it may be interesting to consider systemic
therapy, i.e., immunotherapy, after SIRT because radiation
therapy is known to increase the expression of antigens as
targets for the activated immune system [33,34]. Ongoing
randomized trials may refine the role of SIRT in the near
future as treatment for uveal melanoma without extrahe-
patic metastases.
Conclusion
In our small retrospective study, SIRT was well tolerated and
some treatment benefit was proven. Together with earlier
retrospective studies, our results support that SIRT is safe and
may be given as the first-line therapy to patients with meta-
static uveal melanoma with metastases confined to the liver
not eligible for surgery.
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